

Axitinib is an investigational agent and has not been approved by regulatory agencies.

COMPOUND DESCRIPTION	<p>Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.¹</p>
ABOUT VEGF RECEPTORS	<p>VEGF receptors are thought to play a role in the growth and spread of many tumors, including renal cell carcinoma, breast, lung, thyroid and colorectal cancer.²</p> <p>VEGF receptors 1, 2 and 3 can influence tumor growth, vascular angiogenesis, and progression of cancer (the spread of tumors).²</p> <p>Preclinical evidence suggests that inhibiting all three VEGF receptor signaling pathways may more efficiently disrupt tumor growth, vascular angiogenesis, and metastatic progression of cancer through lymphangiogenesis than by inhibiting an individual pathway.²</p>
CLINICAL STUDIES	<p>Axitinib is being studied as both a single agent and in combination with chemotherapy across several tumor types.</p> <p><u>RCC</u></p> <ul style="list-style-type: none"> • AGILE 1032 (A4061032, NCT00678392): A randomized, Phase 3, open-label trial, (also known as the AXIS trial), evaluating the efficacy and safety study of axitinib versus sorafenib in patients with previously treated advanced renal cell carcinoma (RCC).³ • AGILE 1051 (A4061051, NCT00920816): A randomized, Phase 3 clinical trial evaluating the efficacy and safety of axitinib in patients with treatment-naïve as well as previously treated advanced RCC. • AGILE 1046 (A4061046, NCT00835978): A randomized, double-blind, Phase 2 study is investigating axitinib with or without dose titration in patients with metastatic renal cell carcinoma.⁴ <p><u>HCC</u></p> <ul style="list-style-type: none"> • AGILE 1058 (A4061046, NCT01210495): A randomized, double-blind study of axitinib plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) following failure of one prior antiangiogenic therapy.⁵ This trial is currently open and enrolling.

For more information, please visit www.pfizercancertrials.com or www.clinicaltrials.gov or call toll-free 1-877-369 9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).

¹ ASCO Accepted Abstract # TPS235. Axitinib ± dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). Trials in Progress Poster, Monday, June 7: 8:00am. Eric Jonasch - Presenter. 2010 American Society of Clinical Oncology Annual Meeting. Chicago, IL. June 4 – 8, 2010.

² Hicklin DJ, Ellis LM. Role of VEGF in Tumor Growth and Angiogenesis. *JCO*. 2007;23:1011-1027.

³ ClinicalTrials.gov. Axitinib (Ag 013736) As Second Line Therapy for Metastatic Renal Cell Cancer. Available at:

<http://www.clinicaltrials.gov/ct2/show/NCT00678392?term=axitinib&rank=1>. Accessed May 12th, 2010.

⁴ ClinicalTrials.gov. Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer. Available at:

<http://www.clinicaltrials.gov/ct2/show/NCT00835978>. Accessed May 12th, 2010.

⁵ Clinical Trials.gov. Axitinib For The Treatment of Advanced Hepatocellular Carcinoma. Available at:

<http://clinicaltrials.gov/ct2/show/NCT01210495?term=axitinib&rank=21>. Accessed May 5, 2011.